Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Parkinson's Disease: Overview

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Men's health research priorities in men with multiple sclerosis.

Multiple sclerosis journal - experimental, translational and clinical·2026

Same author

Bruton's Tyrosine Kinase Inhibitors in Multiple Sclerosis.

Drugs·2026

Same author

Use of semaglutide and tirzepatide among people with multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026

Same author

Long-term safety and efficacy of ponesimod in participants with relapsing multiple sclerosis: results from the phase 3 OPTIMUM 5-year long term extension study.

Journal of neurology·2026

Same author

Tolebrutinib Phase 2b Long-Term Extension Study: Two-Year Safety, MRI, and Clinical Efficacy Outcomes in Patients With Relapsing Multiple Sclerosis Patients.

Neurology open access·2026

Same author

Evaluation of cortical pathology in primary-progressive multiple sclerosis: a post hoc analysis of the SPRINT-MS trial.

BMJ neurology open·2026

Same journal

Key Considerations in Telestroke Program Management.

Continuum (Minneapolis, Minn.)·2026

Same journal

Neurology's Action Potential: Delivering on the Promise of Brain Health.

Continuum (Minneapolis, Minn.)·2026

Same journal

Erratum.

Continuum (Minneapolis, Minn.)·2026

Same journal

Management of Large Artery Atherosclerosis.

Continuum (Minneapolis, Minn.)·2026

Same journal

Thrombolysis, Thrombectomy, and Antithrombotic Therapy for Acute Ischemic Stroke.

Continuum (Minneapolis, Minn.)·2026

Same journal

Stroke in Children and Younger Adults.

Continuum (Minneapolis, Minn.)·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Mar 20, 2026

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Published on: November 14, 2016

Progressive Multiple Sclerosis.

Mary Alissa Willis, Robert J Fox

Continuum (Minneapolis, Minn.)

|June 5, 2016

Summary

This summary is machine-generated.

Therapeutic advances for progressive multiple sclerosis (MS) are limited, but symptomatic treatments can improve quality of life. A multidisciplinary approach is crucial for managing progressive MS symptoms.

More Related Videos

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

Related Experiment Videos

Last Updated: Mar 20, 2026

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Published on: November 14, 2016

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

Area of Science:

Neurology
Immunology
Clinical Therapeutics

Background:

Relapsing-remitting multiple sclerosis (MS) has seen significant therapeutic progress, unlike progressive MS.
Current management strategies for progressive MS are primarily symptomatic, with limited disease-modifying options.

Observation:

The 2013 revision of progressive MS classification incorporates inflammatory activity via relapses or imaging.
Understanding progressive MS pathogenesis and comorbidity impact is vital for clinical management and trial design.

Findings:

No current therapies approved for relapsing-remitting MS effectively slow disability progression in progressive MS.
Research is exploring immunomodulatory agents, neuroprotective molecules, stem cells, nutrition, and rehabilitation.

Implications:

A comprehensive, multidisciplinary approach is essential for managing progressive MS symptoms and enhancing patient quality of life.
Future clinical trials will investigate a broad spectrum of interventions for progressive MS.